Silence Therapeutics (SLN) News Today $12.70 -1.28 (-9.16%) (As of 11/15/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Silence Therapeutics (NASDAQ:SLN) Earns Buy Rating from HC WainwrightHC Wainwright reissued a "buy" rating and set a $75.00 price objective on shares of Silence Therapeutics in a research report on Friday.November 15 at 3:28 PM | marketbeat.comSilence Therapeutics plc: Silence Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business HighlightsNovember 14 at 11:24 AM | finanznachrichten.deSilence Therapeutics to Participate in Fireside Chat at the Jefferies London Healthcare ConferenceNovember 14 at 11:24 AM | finance.yahoo.comIs Silence Therapeutics plc (SLN) a Promising Gene Editing Stock?October 31, 2024 | uk.finance.yahoo.comSilence Therapeutics (SLN) Gets a Buy from Morgan StanleyOctober 22, 2024 | markets.businessinsider.comCubist Systematic Strategies LLC Has $179,000 Position in Silence Therapeutics plc (NASDAQ:SLN)Cubist Systematic Strategies LLC lowered its holdings in Silence Therapeutics plc (NASDAQ:SLN - Free Report) by 74.0% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 9,438 shares of the company's stock after sellingOctober 15, 2024 | marketbeat.comRenaissance Technologies LLC Sells 64,800 Shares of Silence Therapeutics plc (NASDAQ:SLN)Renaissance Technologies LLC cut its position in Silence Therapeutics plc (NASDAQ:SLN - Free Report) by 62.4% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 39,100 shares of the company's stock after selliOctober 9, 2024 | marketbeat.comMorgan Stanley Reaffirms Overweight Rating for Silence Therapeutics (NASDAQ:SLN)Morgan Stanley reiterated an "overweight" rating and issued a $49.00 target price on shares of Silence Therapeutics in a report on Tuesday.October 8, 2024 | marketbeat.comMillennium Management LLC Buys 373,523 Shares of Silence Therapeutics plc (NASDAQ:SLN)Millennium Management LLC raised its holdings in shares of Silence Therapeutics plc (NASDAQ:SLN - Free Report) by 91.2% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 782,941 shares of the company's sOctober 7, 2024 | marketbeat.comSilence Therapeutics (NASDAQ:SLN) Stock Price Down 3.7% - Here's What HappenedSilence Therapeutics (NASDAQ:SLN) Stock Price Down 3.7% - What's Next?October 4, 2024 | marketbeat.comSilence Therapeutics (NASDAQ:SLN) Trading 3.6% Higher Silence Therapeutics (NASDAQ:SLN) Shares Up 3.6%October 3, 2024 | marketbeat.comPoint72 Asset Management L.P. Raises Stock Holdings in Silence Therapeutics plc (NASDAQ:SLN)Point72 Asset Management L.P. lifted its holdings in Silence Therapeutics plc (NASDAQ:SLN - Free Report) by 1,686.6% in the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 146,500 shares of the company's stock after purchasing aOctober 3, 2024 | marketbeat.comSilence Therapeutics (NASDAQ:SLN) Sees Large Volume IncreaseSilence Therapeutics (NASDAQ:SLN) Sees Unusually-High Trading VolumeSeptember 25, 2024 | marketbeat.comSilence Therapeutics plc (NASDAQ:SLN) is M28 Capital Management LP's 6th Largest PositionM28 Capital Management LP lowered its position in Silence Therapeutics plc (NASDAQ:SLN - Free Report) by 38.2% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 185,100 shares of the company's stock after selliSeptember 21, 2024 | marketbeat.comSilence Therapeutics (NASDAQ:SLN) Sees Unusually-High Trading VolumeSilence Therapeutics (NASDAQ:SLN) Sees Strong Trading VolumeSeptember 17, 2024 | marketbeat.comSilence Therapeutics plc (NASDAQ:SLN) Sees Significant Drop in Short InterestSilence Therapeutics plc (NASDAQ:SLN - Get Free Report) saw a large drop in short interest during the month of August. As of August 31st, there was short interest totalling 254,600 shares, a drop of 27.4% from the August 15th total of 350,500 shares. Based on an average daily trading volume, of 222,600 shares, the days-to-cover ratio is presently 1.1 days.September 14, 2024 | marketbeat.com537,338 Shares in Silence Therapeutics plc (NASDAQ:SLN) Acquired by First Turn Management LLCFirst Turn Management LLC acquired a new position in shares of Silence Therapeutics plc (NASDAQ:SLN - Free Report) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 537,338 shares of the company's stockSeptember 13, 2024 | marketbeat.comNicholas Investment Partners LP Takes $2.86 Million Position in Silence Therapeutics plc (NASDAQ:SLN)Nicholas Investment Partners LP purchased a new stake in shares of Silence Therapeutics plc (NASDAQ:SLN - Free Report) during the second quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 150,480 shares of the company's stock, valued at approximately $2September 12, 2024 | marketbeat.comSilence: Additional siRNA Drug Data Leads To Next Stages Of DevelopmentSeptember 5, 2024 | seekingalpha.comSilence Therapeutics (NASDAQ:SLN) Now Covered by Analysts at Jefferies Financial GroupJefferies Financial Group began coverage on Silence Therapeutics in a research note on Tuesday. They issued a "buy" rating and a $40.00 price objective on the stock.September 3, 2024 | marketbeat.comSilence Therapeutics (NASDAQ:SLN) Receives Buy Rating from HC WainwrightHC Wainwright reaffirmed a "buy" rating and set a $75.00 target price on shares of Silence Therapeutics in a research report on Friday.August 30, 2024 | marketbeat.comSilence Therapeutics plc (NASDAQ:SLN) Short Interest Down 37.5% in AugustSilence Therapeutics plc (NASDAQ:SLN - Get Free Report) was the target of a significant drop in short interest in the month of August. As of August 15th, there was short interest totalling 350,500 shares, a drop of 37.5% from the July 31st total of 561,200 shares. Based on an average trading volume of 212,000 shares, the short-interest ratio is currently 1.7 days.August 28, 2024 | marketbeat.comLegato Capital Management LLC Takes $376,000 Position in Silence Therapeutics plc (NASDAQ:SLN)Legato Capital Management LLC bought a new position in shares of Silence Therapeutics plc (NASDAQ:SLN - Free Report) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 19,800 shares of the company's stock, valued atAugust 27, 2024 | marketbeat.comSilence Therapeutics to Webcast Presentations at Upcoming September Investor ConferencesAugust 27, 2024 | businesswire.comSilence Therapeutics (NASDAQ:SLN) Trading 4.6% Higher Silence Therapeutics (NASDAQ:SLN) Trading Up 4.6%August 26, 2024 | marketbeat.comBuy Rating Affirmed for Silence Therapeutics Amid Strong Pipeline Progress and Strategic PartnershipsAugust 16, 2024 | markets.businessinsider.comAnalyst Expectations For Silence Therapeutics's FutureAugust 16, 2024 | benzinga.comChardan Capital Reiterates Buy Rating for Silence Therapeutics (NASDAQ:SLN)Chardan Capital reaffirmed a "buy" rating and set a $55.00 target price on shares of Silence Therapeutics in a research note on Friday.August 16, 2024 | marketbeat.comAnalysts Conflicted on These Healthcare Names: MiNK Therapeutics (INKT), Silence Therapeutics (SLN) and Mersana Therapeutics (MRSN)August 16, 2024 | markets.businessinsider.comSLN Stock Earnings: Silence Therapeutics Reported Results for Q2 2024August 15, 2024 | investorplace.comSilence Therapeutics plc: Silence Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business HighlightsAugust 15, 2024 | finanznachrichten.deSilence Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business HighlightsAugust 15, 2024 | stockhouse.comSG Americas Securities LLC Raises Holdings in Silence Therapeutics plc (NASDAQ:SLN)SG Americas Securities LLC grew its position in shares of Silence Therapeutics plc (NASDAQ:SLN - Free Report) by 4,802.8% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 343,196 shareAugust 11, 2024 | marketbeat.comThe 3 Best Gene Editing Stocks to Buy in August 2024August 7, 2024 | investorplace.comSilence Therapeutics (NASDAQ:SLN) Trading Down 9.5%Silence Therapeutics (NASDAQ:SLN) Shares Down 9.5%August 5, 2024 | marketbeat.comJanus Henderson Group PLC Invests $13.58 Million in Silence Therapeutics plc (NASDAQ:SLN)Janus Henderson Group PLC purchased a new position in Silence Therapeutics plc (NASDAQ:SLN - Free Report) in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 625,864 shares of the company's stock, valued at aAugust 1, 2024 | marketbeat.comSilence Therapeutics (NASDAQ:SLN) Stock Price Down 5.6%Silence Therapeutics (NASDAQ:SLN) Shares Down 5.6%July 30, 2024 | marketbeat.comSilence Therapeutics plc (NASDAQ:SLN) Short Interest Down 26.1% in JulySilence Therapeutics plc (NASDAQ:SLN - Get Free Report) saw a large decrease in short interest during the month of July. As of July 15th, there was short interest totalling 560,700 shares, a decrease of 26.1% from the June 30th total of 759,200 shares. Based on an average daily trading volume, of 157,700 shares, the short-interest ratio is currently 3.6 days.July 27, 2024 | marketbeat.comAnalysts Offer Insights on Healthcare Companies: Danaher (DHR), Silence Therapeutics (SLN) and Exscientia Plc (EXAI)July 22, 2024 | markets.businessinsider.comSilence Therapeutics (NASDAQ:SLN) Stock Price Down 2.5%Silence Therapeutics (NASDAQ:SLN) Shares Down 2.5%July 12, 2024 | marketbeat.comSilence Therapeutics (NASDAQ:SLN) Trading Down 3.5%Silence Therapeutics (NASDAQ:SLN) Stock Price Down 3.5%July 2, 2024 | marketbeat.comSilence Therapeutics (NASDAQ:SLN) PT Raised to $49.00 at Morgan StanleyMorgan Stanley boosted their price objective on Silence Therapeutics from $45.00 to $49.00 and gave the company an "overweight" rating in a research note on Friday.June 28, 2024 | marketbeat.comSilence Therapeutics (NASDAQ:SLN) Shares Gap Up on Analyst UpgradeSilence Therapeutics (NASDAQ:SLN) Shares Gap Up Following Analyst UpgradeJune 28, 2024 | marketbeat.comSilence Therapeutics (NASDAQ:SLN) Rating Reiterated by HC WainwrightHC Wainwright reiterated a "buy" rating and issued a $75.00 target price on shares of Silence Therapeutics in a research note on Thursday.June 27, 2024 | marketbeat.comSilence Therapeutics (NASDAQ:SLN) Shares Down 4.9% Silence Therapeutics (NASDAQ:SLN) Trading Down 4.9%June 26, 2024 | marketbeat.comSilence Therapeutics (NASDAQ:SLN) Trading 4% Higher Silence Therapeutics (NASDAQ:SLN) Trading Up 4%June 24, 2024 | marketbeat.comSilence Therapeutics Achieves $2 Million Research Milestone Payment from Hansoh Pharma CollaborationJune 24, 2024 | businesswire.comSilence Therapeutics: PV Data For Consideration After ASCVD Treatment ResultsJune 21, 2024 | seekingalpha.comSilence Therapeutics (NASDAQ:SLN) Stock Rating Reaffirmed by HC WainwrightHC Wainwright reiterated a "buy" rating and issued a $75.00 price target on shares of Silence Therapeutics in a research note on Thursday.June 20, 2024 | marketbeat.comSilence Therapeutics (NASDAQ:SLN) Shares Gap Up to $18.90Silence Therapeutics (NASDAQ:SLN) Shares Gap Up to $18.90June 20, 2024 | marketbeat.com Get Silence Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SLN and its competitors with MarketBeat's FREE daily newsletter. Email Address 5 Stocks that could triple in a week (Ad)Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942%, and 12,592% in 2020. Now their next one could be here. Click here to pay just $5 for a full year of Stealth Trades SLN Media Mentions By Week SLN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SLN News Sentiment▼0.410.56▲Average Medical News Sentiment SLN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SLN Articles This Week▼62▲SLN Articles Average Week Get Silence Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SLN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies CNTA News NRIX News IRON News SYRE News TARS News ARVN News GLPG News NTLA News IMCR News KNSA News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SLN) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Silence Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Silence Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
